- 0xfaster identification of relevant scientific evidence
- 0%faster preparation of regulatory submission
- 0%scientific knowledge accuracy
- 0%reduction in costly clinical trial amendments
Transform scientific literature and clinical evidence into connected insights that accelerate biomarker discovery and personalized treatment strategies.
This is where researchers, clinical development teams, regulatory affairs professionals, medical affairs teams, and IP specialists interact with AI, and where trust is built. AI delivers context-rich insights, explains the evidence behind recommendations, and defers to human expertise whenever scientific, regulatory, or business judgment is required. Every insight is fully traceable to its originating source, whether a publication, clinical study, regulatory document, patent, or internal knowledge asset. Purpose-built applications provide role-specific experiences, ensuring the right information reaches the right expert at the moment of decision.
The challenge
Before a first-in-human IND, regulatory writers build the nonclinical summaries of CTD Module 2 and the Investigator's Brochure from a dozen or more GLP study reports. Every dose, NOAEL and exposure must match its source, and the same value often appears in three or four documents. Quality control against source is still done by hand, line by line, and this is where review cycles slip. Here, a regulatory writer verifies the Toxicology Written Summary against six study reports: 214 data points extracted from text and tables, five discrepancies. The most serious is a rat NOAEL that holds only for females; the male value sits in a source table.
How the AI works
The verified values are then checked across the whole package. The wrong NOAEL appears in all four documents and the wrong dog exposure in three, so the safety margin built on it is recalculated from the verified input, from 15× to 12×. A missing Ames entry and a broken cross-reference against the submission template are flagged too. The writer applies 14 verified fixes as tracked changes in one click. The AI then drafts the corrected repeat-dose paragraph and the missing genotoxicity entry from the source reports, linking every sentence to the page or table it came from. Nothing changes until the writer accepts it.
Verified, traceable, review-ready
The package reaches quality review with its evidence attached. All five discrepancies and 15 consistency findings are resolved, and 128 of 128 statements link to a source page or table. The one item the AI cannot close, a pending signature on a study report, is shown with an owner and a due date rather than hidden. The writer sends version 1.3 to the QA reviewer, and the audit trail records who decided each change, when and on what evidence. Less manual checking, fewer surprises in review and a nonclinical package that stands up to scrutiny. Neurosymbolic AI: enterprise-grade, domain-specific, built for regulated industries.
The challenge
Protocol amendments are among the most expensive and avoidable events in clinical development: each one adds site and ethics committee work, slows recruitment and delays time to market, and oncology is hit hardest. ICH E8(R1) asks sponsors to build quality into the design, yet teams still benchmark by hand against the few trials they already know. Here, a protocol design lead tests a draft Phase II lung cancer protocol before internal review. The draft is parsed and matched against more than 900,000 historical trials, narrowing to 38 comparable studies. 19 of them needed a substantial amendment, most often to eligibility.
How the AI works
Each eligibility criterion is benchmarked against the comparable studies, and its impact is estimated in a de-identified real-world cohort. Four criteria are stricter than most comparable trials. The AI proposes evidence-backed changes to three and refers the renal threshold to Clinical Pharmacology; the QTc limit stays, because the Investigator's Brochure gives a safety reason. The protocol lead accepts the three changes as tracked edits, and the estimated eligible share rises from 14% to 29%. Endpoints and assessments come next: progression-free survival is aligned and the control-arm assumption sits within the observed range, but a mandatory on-treatment biopsy stands out as a frequent amendment trigger.
Evidence-backed, explainable, review-ready
Every amendment risk signal sits in one register, each backed by the number of comparable studies in which the same choice was later amended, not by a predictive score. The protocol lead makes the biopsy optional and the overall level moves from High to Moderate; the two remaining items have named owners in Clinical Pharmacology and Regulatory Affairs. One click drafts a design justification for the Protocol Review Committee, with each finding cited to the evidence set, the literature, the real-world cohort or the drug data, and every decision logged. Neurosymbolic AI: enterprise-grade, domain-specific, built for regulated industries.
Celebrating Innovation, the Award Recognizes Expert.ai’s solution for regulatory workflows.
Regulatory submissions require teams to reconcile clinical, scientific and regulatory data while ensuring consistency, traceability and compliance. Manual, fragmented processes can delay submissions and increase risk. Expert.ai addresses these challenges with an intelligent framework combining document generation, quality control and source verification. Its modular agentic architecture separates generation and validation into coordinated AI workflows within an easy-to-use solution.
Expert.ai Recognized as a Sample Vendor in Composite AI
Expert.ai sees the mention as confirmation that no single AI technique can carry mission-critical, regulated workflows alone. Precision, explainability, value creation and cost efficiency all have to work together. Composite AI provides the answer.
Expert.ai Recognized for Turning Data into Reliable, Explainable and Scalable Decisions.
Text: What differentiates Expert.ai is the ability to operationalize AI within existing enterprise workflows, accelerating time to value without compromising transparency, governance, or control. Expert.ai's mission is to help organizations make faster, more reliable decisions while optimizing the cost and scalability of AI adoption. By going beyond data processing, Expert.ai enables AI that augments and scales human expertise, consistently delivering measurable impact at scale.
Expert.ai Recognized as a Sample Vendor
For organizations exploring agentic AI, the growing role of neurosymbolic approaches underscores the importance of combining advanced AI models with structured knowledge, domain expertise and mechanisms that can provide greater control over AI-driven decisions and processes.
How to Enable Trustworthy, Explainable Agentic AI With Knowledge Graphs in Life Science
As current AI agents often lack the reliability, precision, transparency and contextual understanding required for meaningful clinical and scientific applications, the ability to ground AI-generated outputs in verifiable knowledge is becoming essential. For healthcare and life sciences organizations, the combination of knowledge graphs and agentic AI represents an architectural approach to making AI systems more reliable, explainable and controllable.
Neuro-symbolic AI brings together two kinds of intelligence that complement each other. Neural AI, meaning large language models and machine learning, reads and generates language at scale. Symbolic AI, meaning ontologies, knowledge graphs and scientific and regulatory rules, supplies precise domain meaning and logical reasoning. Each covers the other’s limits: neural models bring speed and flexibility, while symbolic knowledge brings accuracy, consistency and explainability. For life sciences, this means AI that can process huge volumes of literature, clinical data and regulatory content while respecting the exact meaning of terms like “adverse event” or “primary endpoint.” It also shows the evidence behind every output. Gartner recognized Expert.ai as a Sample Vendor in its 2026 report Neurosymbolic AI, a Shortcut to Agentic Systems Governance.